TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12604982
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LGG treatment) for infants <1500 g
Study: 12604982
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LGG treatment) for infants 1500 to 1999 g
Study: 10690513
Drug: HuM195 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HuM195 treatment
Study: 10690513
Drug: HuM195 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HuM195 treatment after RA alone
Study: 10690513
Drug: HuM195 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HuM195 treatment in newly diagnosed APL
Study: 10690513
Drug: HuM195 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HuM195 treatment in second or third remission
Study: 9327292
Drug: Tenoxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (20 mg daily)
Study: 2878680
Drug: xamoterol 200
Normalized name: xamoterol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoterol 200 mg
Study: 30028484
Drug: High-protein enteral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein enteral diet providing 3 g ß‐glucan
Study: 30028484
Drug: Placebo diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo diet with 3 g maltodextrin
Study: 24756009
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg/day) plus metadoxine (500 mg three times daily)
Study: 22322966
Drug: Topical α‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical α‐2 agonist brimonidine
Study: 22322966
Drug: Goal‐directed intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal‐directed intravenous administration of 5% albumin
Study: 22322966
Drug: Goal‐directed administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal‐directed administration of lactated Ringer's solution
Study: 20196184
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (6-9 months)
Study: 16183427
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg) plus insulin
Study: 12955901
Drug: Novel antipsychotic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel antipsychotic drugs
Study: 10727880
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of co-artemether and mefloquine
Study: 8855983
Drug: IL-2 with
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 with levamisole (50 mg t.d.s. p.o. on days 1-3 on alternate weeks)
Study: 30575489
Drug: Zoledronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate (5 mg)
Study: 27798337
Drug: GOS +
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOS + 0.2 g 2'‐FL/L
Study: 27798337
Drug: GOS +
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOS + 1.0 g 2'‐FL/L
Study: 20061328
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (PUFA) capsules, 1240 mg eicosapentaenoic acid and 1000 mg docosahexaenoic acid, for 5-7 days prior to surgery and post-operatively until hospital discharge
Study: 20061328
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil capsules for 5-7 days prior to surgery and post-operatively until hospital discharge
Study: 12433819
Drug: R (ritonavir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R (ritonavir) 400 mg given simultaneously with S (saquinavir) 800 mg
Study: 12433819
Drug: N (nelfinavir)
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N (nelfinavir) 750 mg given simultaneously with S (saquinavir) 800 mg
Study: 12433819
Drug: R (ritonavir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R (ritonavir) 400 mg
Study: 10725786
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (2 mg/kg/day) for 12 weeks
Study: 7795774
Drug: 2.5% selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% selenium sulfide lotion
Study: 1954072
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for 11 days
Study: 1954072
Drug: Digoxin 1
Normalized name: DIGOXIN 125MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 1 mg alone (control)
Study: 7007474
Drug: Preseasonal intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preseasonal intranasal short ragweed (SRW) immunotherapy, sprayed SRW solutions intranasally six times a day for 12 weeks
Study: 7007474
Drug: Preseasonal intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preseasonal intranasal short ragweed (SRW) immunotherapy
Study: 7007474
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with nebulized solutions containing buffer or histamine
Study: 31402321
Drug: Letrozole plus
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole plus taselisib (4 mg orally, on a 5 days-on, 2 days-off schedule for 16 weeks)
Study: 28647383
Drug: Agaricus bisporus
Normalized name: Agaricus bisporus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agaricus bisporus mushrooms (226 g)
Study: 28647383
Drug: Meat (28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat (28 g)
Study: 25210140
Drug: Norovirus GI.1/GII.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norovirus GI.1/GII.4 bivalent vaccine-like particle (VLP) vaccine with 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and alum
Study: 25210140
Drug: Norovirus GI.1/GII.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norovirus GI.1/GII.4 bivalent vaccine-like particle (VLP) vaccine
Study: 21083671
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 400 mg every 4 weeks (n = 28)
Study: 30779339
Drug: Tezepelumab (AMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab (AMG 157) 35 mg
Study: 30779339
Drug: Tezepelumab (AMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab (AMG 157) 105 mg
Study: 30779339
Drug: Tezepelumab (AMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab (AMG 157) 210 mg
Study: 30779339
Drug: Tezepelumab (AMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab (AMG 157) 210 mg every 28 days
Study: 30779339
Drug: Tezepelumab (AMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab (AMG 157) 210 mg every 14 days
Study: 30779339
Drug: Tezepelumab (AMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab (AMG 157) 210 mg every 7 days
Study: 26156560
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 (phylloquinone) 10 mg/day for 8 weeks
Study: 12417283
Drug: apo A‐I
Approvals — FDA: no, EMA: no, PMDA: no
Description: apo A‐I <1.2 g/l
Study: 12417283
Drug: apo B
Approvals — FDA: no, EMA: no, PMDA: no
Description: apo B > or =1.4 g/l
Study: 2200382
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg every 12 hours)
Study: 2200382
Drug: Verapamil sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil sustained release (240 mg/d)
Study: 31563659
Drug: Awake sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awake sedation with target controlled propofol infusion
Study: 30472337
Drug: 0.075% capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075% capsaicin lotion
Study: 23371961
Drug: Steroid-sensitive nephrotic
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-sensitive nephrotic syndrome
Study: 7805356
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil (1500 mg)
Study: 7805356
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil (800 or 1000 mg)
Study: 7805356
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil (400 or 500 mg)
Study: 7805356
Drug: Comparators (spectinomycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparators (spectinomycin, thiamphenicol, ampicillin, or amoxicillin plus probenecid)
Study: 23850318
Drug: Personalized antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized antiplatelet therapy according to CYP2C19 phenotype
Study: 23850318
Drug: Conventional antiplatelet
Normalized name: magaldrate and antiflatulents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antiplatelet treatment
Study: 21596876
Drug: Remifentanil 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.2 μg/kg/min (group HI)
Study: 21596876
Drug: Remifentanil 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.05 μg/kg/min (group LO)
Study: 21596876
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 30 mg/kg at induction followed by 10 mg/kg/h (group HM)
Study: 9359709
Drug: Recombinant herpes
Normalized name: Dna (recombinant herpes simplex virus type 1 strain kos plasmid vector kb103 human collagen col7a1-specifying)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant herpes simplex virus type 2 glycoproteins D and B vaccine in MF59 adjuvant
Study: 8269444
Drug: Low-dose bisoprolol/HCTZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose bisoprolol/HCTZ 6.25 mg
Study: 8269444
Drug: Monotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy and placebo
Study: 3946169
Drug: Oral amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiodarone (30 mg/kg)
Study: 30461306
Drug: Avelumab in
Normalized name: avelumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab in combination with chemoradiotherapy (CRT)
Study: 30461306
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with chemoradiotherapy (CRT)
Study: 28213776
Drug: Target Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target Controlled Infusion (TCI) sedation endoscopy (TCI-DISE)
Study: 28213776
Drug: Target Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target Controlled Infusion (TCI-DISE)
Study: 22092126
Drug: Fentanyl 0
Normalized name: fentanyl 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0 mcg/kg (F0)
Study: 22092126
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 mcg/kg (F1)
Study: 22092126
Drug: Fentanyl 1.5
Normalized name: fentanyl 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.5 mcg/kg (F1.5)
Study: 22092126
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 mcg/kg (F2)
Study: 17035445
Drug: Intranasal trivalent,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal trivalent, live attenuated, cold‐adapted influenza virus vaccine (TC)
Study: 17035445
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo (TP)
Study: 15167171
Drug: Enoxaparin or
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin or unfractionated heparin (control)
Study: 8213578
Drug: Enalapril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (1 mg infusion followed by oral treatment to a target dose of 20 mg/day)
Study: 3315271
Drug: BID (twice-daily,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID (twice-daily, equally divided 12 hr)
Study: 3315271
Drug: OD-PM (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: OD-PM (once-daily evening)
Study: 3315271
Drug: OD-AM (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: OD-AM (once-daily morning)
Study: 25175480
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate combination inhaler (SFC)
Study: 25175480
Drug: No FP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No FP dose change
Study: 25175480
Drug: Increased FP
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased FP dose
Study: 18724209
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ITB treatment)
Study: 15910297
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) administered at a daily oral dose of 2 x 1000 mg for the first 6 postoperative months, tapered within 2 weeks thereafter.
Study: 15910297
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received fluocortolon and topical prednisolone acetate, no specific intervention mentioned.
Study: 11156812
Drug: Bupropion (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (up to 200 mg b.i.d.)
Study: 9625292
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus nicotinamide (0.5 g, three tablets/day)
Study: 9625292
Drug: Current sulphonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current sulphonylureas plus nicotinamide (0.5 g, three tablets/day)
Study: 9625292
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus placebo (3 tablets/day)
Study: 7836197
Drug: Dipyridamole (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (0.6 mg/kg)
Study: 3282078
Drug: Interferon alfa-2B
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2B therapy for an additional 6 months (18 months total)
Study: 3282078
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy after 12 months of interferon alfa-2B
Study: 3282078
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with interferon alfa-2B after relapse
Study: 3282078
Drug: Interferon alfa-2B
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2B therapy (standard dose of 2 X 10(6) U/m2 sc three times weekly)
Study: 29409133
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg (anti-TNF-naive)
Study: 29409133
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg (anti-TNF-naive)
Study: 29409133
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg (anti-TNF-IR)
Study: 29409133
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg (anti-TNF-IR)
Study: 28013272
Drug: CSC-T (8-session,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSC-T (8-session, group-based comprehensive smoking cessation and trauma management treatment)
Study: 21612744
Drug: Amikacin 125
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin 125 ‐ 1,000 mg once‐daily or every‐other‐day
Study: 17183433
Drug: Transfer after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer after initial treatment in local emergency room (group 2)
Study: 17183433
Drug: Transfer after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer after initial treatment in local emergency room (group 3)
Study: 15271158
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid warmer set at 38.5 degrees C on the dialysate and 1 L/hour of replacement fluid lines
Study: 7898095
Drug: Systemic antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antihypertensive therapy
Study: 28394459
Drug: Placebo (719
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (719 mg maltodextrin)
Study: 21700360
Drug: 5% minoxidil
Normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% minoxidil topical foam (MTF) once daily
Study: 21700360
Drug: 2% minoxidil
Normalized name: MINOXIDIL 2 g in 100 mL TOPICAL LIQUID [2% Minoxidil hair growth serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% minoxidil topical solution (MTS) twice daily
Study: 7638994
Drug: Systemic narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic narcotic medications
Study: 2507224
Drug: Enteral feeding
Normalized name: enteral feeding dispenser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral feeding via needle catheter jejunostomy (NCJ) starting 12 hours postoperatively, advanced to 100-125 ml/h of full-strength diet
Study: 782777
Drug: Amine fluoride
Normalized name: triethylene amine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine fluoride daily
Study: 782777
Drug: Acidulated phosphate
Normalized name: Acidulated Phosphate Fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidulated phosphate fluoride daily
Study: 782777
Drug: Amine fluoride
Normalized name: triethylene amine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine fluoride weekly
Study: 782777
Drug: Placebo weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo weekly
Study: 23429913
Drug: GSK961081 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK961081 (400 μg once daily)
Study: 23429913
Drug: GSK961081 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK961081 (200 μg twice daily)
Study: 16877299
Drug: D-Ala1-peptide T-amide
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Ala1-peptide T-amide (DAPTA) at a dose of 2 mg three times per day (tid)
Study: 1356459
Drug: Fosfomycin 8
Normalized name: FOSFOMYCIN
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin 8 g and metronidazole 1 g before operation and fosfomycin 8 g eight hours afterwards
Study: 1356459
Drug: Doxycycline 400
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 400 mg and metronidazole 1 g before operation, and placebo eight hours afterwards
Study: 29193234
Drug: Ropivacaine-dexmedetomidine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine-dexmedetomidine group (group RD, n = 19) received 15 mL of 0.5% ropivacaine with 100 μg (1 mL) dexmedetomidine
Study: 25326169
Drug: Eptifibatide (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (0.2 mg/kg intra-arterial bolus)
Study: 25326169
Drug: Heparin and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and/or aspirin (control group)
Study: 17157651
Drug: Rescue medications
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medications and peak flow measurements
Study: 12232545
Drug: Agomelatine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 5 mg
Study: 12232545
Drug: Agomelatine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 100 mg
Study: 11503260
Drug: Ceftibuten, 400
Normalized name: Ceftibuten, 400 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten, 400 mg once daily
Study: 11503260
Drug: Other antibiotics
Normalized name: Other antibiotics for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antibiotics (b.i.d. dosing)
Study: 11503260
Drug: Other antibiotics
Normalized name: Other antibiotics for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antibiotics (t.i.d. dosing)
Study: 11503260
Drug: Dosing frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing frequency
Study: 8184352
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment including specific manual treatment, such as manipulation and specific mobilization, muscle stretching, auto-traction, and cortisone injections
Study: 8184352
Drug: Conventional activating
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional activating treatment
Study: 26152416
Drug: Emodepside/Praziquantel Spot-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emodepside/Praziquantel Spot-on (Profender®) - single application (3 mg/kg emodepside and 12 mg/kg praziquantel)
Study: 21176949
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance (375 mg/m² every 8 weeks)
Study: 18279829
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol 2.0 mg/day for 2 weeks
Study: 18279829
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol 4.0 mg/day
Study: 18279829
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol 2.0 mg/day + medroxyprogesterone acetate
Study: 18279829
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 50 microg
Study: 12456499
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy with factor XIIIA Leu34 allele
Study: 12456499
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy with factor XIIIB Arg95 allele
Study: 8592524
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (100 mg per day) and subcutaneous erythropoietin (150 U per kilogram of body weight twice per week)
Study: 8592524
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron and placebo
Study: 1955630
Drug: Budesonide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (4 weeks treatment)